Global Montelukast API Market

Montelukast API Comprehensive Study by Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline), Application (Asthma,, Allergic Rhinitis, Bronchospasm, Urticaria, Others), Dosage Form (Tablets, Chewable Tablets, Oral Solutions) Players and Region - Global Market Outlook to 2030

Montelukast API Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Montelukast API
Montekulast API market is expected to mark significant growth over forecasted period owing to incidence inasthma, exercise induced bronchospasm, allergic rhinitis, primary dysmenorrhea and urticaria. Montekulast API offers driving the growth of this market are the rise in respiratory diseases coupled with the growing geriatric population. The Increasing Research and Development investments to develop novel drugs and the advancements in technology will create lucrative opportunities for key market players.

AttributesDetails
Study Period201-2030
Base Year2023
UnitValue (USD Million)
CAGR11.4%


Market players are focusing on partnerships, collaborations, and new product launches in order to increase their offerings in the notching machines market. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product offerings. Analyst at AMA Research estimates that United States Vendors will contribute the maximum growth to Global Montelukast API market throughout the forecasted period. Established and emerging Vendors should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Sharp & Dohme Corp (United States), Dr. Reddy’s Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd (Israel), Hikma Pharmaceuticals PLC (United Kingdom), Glenmark (India), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (United States) and Hetero (India) are some of the key players that are part of study coverage. Additionally, the Vendors which are also part of the research coverage are Aurobindo Pharma (India), Unimark Remedies (India), Jubilant Cadista (United States) and Aamorb Pharmaceuticals (India).

Segmentation Overview
AMA Research has segmented the market of Global Montelukast API market by Type (Montelukast Sodium Amorphous and Montelukast Sodium Crystalline), Application (Asthma,, Allergic Rhinitis, Bronchospasm, Urticaria and Others) and Region.



On the basis of geography, the market of Montelukast API has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Dosage Form, the sub-segment i.e. Tablets will boost the Montelukast API market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Implementation of Rules and Regulations in Montekulast API market.

Market Growth Drivers:
Increase Incidence of Asthma Patients. and Incidence of Environmental Allergens Due to Industrialization and Pollution.

Challenges:
Lack Of Research And Development In The Industry Are Anticipated The Challenge The Market.

Restraints:
Availability of Substitute’s Products Hampers The Montelukast API Market. and Adverse Effect Associated With Montekulast API.

Opportunities:
Technological Advancements Leads To Boost The Montelukast API Market. and Upsurge Demand of Montekulast API in Asia-Pacific Regions.

Market Leaders and their expansionary development strategies
On April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
In December 2021, Morepen Laboratories Limited has received USFDA approval for its anti-allergy drug Fexofinadine Hydrochloride that is marketed in India under the popular brand name Allegra, among others and is the block buster drug of the innovator company Sanofi
“According to U.S. Food and Drug Administration, its confirmed that Morepen gets clearance for anti-asthamatic drugs montekulast that essential for manufacturing under strict quality control complying with cGMP requirements and meeting various other global manufacturing standards having already obtained COS (Certificate of Suitability) in Europe and IDL (Import Drug Licence) from China.”

Key Target Audience
Montekulast API Manufacturers, Montekulast API Traders, End-Use Market Participants of Different Segments of Montekulast API, Government and Research Organizations, R&D Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Montelukast Sodium Amorphous
  • Montelukast Sodium Crystalline
By Application
  • Asthma,
  • Allergic Rhinitis
  • Bronchospasm
  • Urticaria
  • Others
By Dosage Form
  • Tablets
  • Chewable Tablets
  • Oral Solutions

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Incidence of Asthma Patients.
      • 3.2.2. Incidence of Environmental Allergens Due to Industrialization and Pollution.
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Research And Development In The Industry Are Anticipated The Challenge The Market.
    • 3.4. Market Trends
      • 3.4.1. Implementation of Rules and Regulations in Montekulast API market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Montelukast API, by Type, Application, Dosage Form and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Montelukast API (Value)
      • 5.2.1. Global Montelukast API by: Type (Value)
        • 5.2.1.1. Montelukast Sodium Amorphous
        • 5.2.1.2. Montelukast Sodium Crystalline
      • 5.2.2. Global Montelukast API by: Application (Value)
        • 5.2.2.1. Asthma,
        • 5.2.2.2. Allergic Rhinitis
        • 5.2.2.3. Bronchospasm
        • 5.2.2.4. Urticaria
        • 5.2.2.5. Others
      • 5.2.3. Global Montelukast API by: Dosage Form (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Chewable Tablets
        • 5.2.3.3. Oral Solutions
      • 5.2.4. Global Montelukast API Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Montelukast API (Price)
      • 5.3.1. Global Montelukast API by: Type (Price)
  • 6. Montelukast API: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Sharp & Dohme Corp (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Dr. Reddy’s Laboratories Ltd (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Morepen Laboratories Ltd (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Glenmark (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz International GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vintage Pharmaceuticals Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hetero (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Montelukast API Sale, by Type, Application, Dosage Form and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Montelukast API (Value)
      • 7.2.1. Global Montelukast API by: Type (Value)
        • 7.2.1.1. Montelukast Sodium Amorphous
        • 7.2.1.2. Montelukast Sodium Crystalline
      • 7.2.2. Global Montelukast API by: Application (Value)
        • 7.2.2.1. Asthma,
        • 7.2.2.2. Allergic Rhinitis
        • 7.2.2.3. Bronchospasm
        • 7.2.2.4. Urticaria
        • 7.2.2.5. Others
      • 7.2.3. Global Montelukast API by: Dosage Form (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Chewable Tablets
        • 7.2.3.3. Oral Solutions
      • 7.2.4. Global Montelukast API Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Montelukast API (Price)
      • 7.3.1. Global Montelukast API by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Montelukast API: by Type(USD Million)
  • Table 2. Montelukast API Montelukast Sodium Amorphous , by Region USD Million (2018-2023)
  • Table 3. Montelukast API Montelukast Sodium Crystalline , by Region USD Million (2018-2023)
  • Table 4. Montelukast API: by Application(USD Million)
  • Table 5. Montelukast API Asthma, , by Region USD Million (2018-2023)
  • Table 6. Montelukast API Allergic Rhinitis , by Region USD Million (2018-2023)
  • Table 7. Montelukast API Bronchospasm , by Region USD Million (2018-2023)
  • Table 8. Montelukast API Urticaria , by Region USD Million (2018-2023)
  • Table 9. Montelukast API Others , by Region USD Million (2018-2023)
  • Table 10. Montelukast API: by Dosage Form(USD Million)
  • Table 11. Montelukast API Tablets , by Region USD Million (2018-2023)
  • Table 12. Montelukast API Chewable Tablets , by Region USD Million (2018-2023)
  • Table 13. Montelukast API Oral Solutions , by Region USD Million (2018-2023)
  • Table 14. South America Montelukast API, by Country USD Million (2018-2023)
  • Table 15. South America Montelukast API, by Type USD Million (2018-2023)
  • Table 16. South America Montelukast API, by Application USD Million (2018-2023)
  • Table 17. South America Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 18. Brazil Montelukast API, by Type USD Million (2018-2023)
  • Table 19. Brazil Montelukast API, by Application USD Million (2018-2023)
  • Table 20. Brazil Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 21. Argentina Montelukast API, by Type USD Million (2018-2023)
  • Table 22. Argentina Montelukast API, by Application USD Million (2018-2023)
  • Table 23. Argentina Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 24. Rest of South America Montelukast API, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Montelukast API, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 27. Asia Pacific Montelukast API, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Montelukast API, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Montelukast API, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 31. China Montelukast API, by Type USD Million (2018-2023)
  • Table 32. China Montelukast API, by Application USD Million (2018-2023)
  • Table 33. China Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 34. Japan Montelukast API, by Type USD Million (2018-2023)
  • Table 35. Japan Montelukast API, by Application USD Million (2018-2023)
  • Table 36. Japan Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 37. India Montelukast API, by Type USD Million (2018-2023)
  • Table 38. India Montelukast API, by Application USD Million (2018-2023)
  • Table 39. India Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 40. South Korea Montelukast API, by Type USD Million (2018-2023)
  • Table 41. South Korea Montelukast API, by Application USD Million (2018-2023)
  • Table 42. South Korea Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 43. Taiwan Montelukast API, by Type USD Million (2018-2023)
  • Table 44. Taiwan Montelukast API, by Application USD Million (2018-2023)
  • Table 45. Taiwan Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 46. Australia Montelukast API, by Type USD Million (2018-2023)
  • Table 47. Australia Montelukast API, by Application USD Million (2018-2023)
  • Table 48. Australia Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Montelukast API, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Montelukast API, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 52. Europe Montelukast API, by Country USD Million (2018-2023)
  • Table 53. Europe Montelukast API, by Type USD Million (2018-2023)
  • Table 54. Europe Montelukast API, by Application USD Million (2018-2023)
  • Table 55. Europe Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 56. Germany Montelukast API, by Type USD Million (2018-2023)
  • Table 57. Germany Montelukast API, by Application USD Million (2018-2023)
  • Table 58. Germany Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 59. France Montelukast API, by Type USD Million (2018-2023)
  • Table 60. France Montelukast API, by Application USD Million (2018-2023)
  • Table 61. France Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 62. Italy Montelukast API, by Type USD Million (2018-2023)
  • Table 63. Italy Montelukast API, by Application USD Million (2018-2023)
  • Table 64. Italy Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 65. United Kingdom Montelukast API, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Montelukast API, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 68. Netherlands Montelukast API, by Type USD Million (2018-2023)
  • Table 69. Netherlands Montelukast API, by Application USD Million (2018-2023)
  • Table 70. Netherlands Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 71. Rest of Europe Montelukast API, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Montelukast API, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 74. MEA Montelukast API, by Country USD Million (2018-2023)
  • Table 75. MEA Montelukast API, by Type USD Million (2018-2023)
  • Table 76. MEA Montelukast API, by Application USD Million (2018-2023)
  • Table 77. MEA Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 78. Middle East Montelukast API, by Type USD Million (2018-2023)
  • Table 79. Middle East Montelukast API, by Application USD Million (2018-2023)
  • Table 80. Middle East Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 81. Africa Montelukast API, by Type USD Million (2018-2023)
  • Table 82. Africa Montelukast API, by Application USD Million (2018-2023)
  • Table 83. Africa Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 84. North America Montelukast API, by Country USD Million (2018-2023)
  • Table 85. North America Montelukast API, by Type USD Million (2018-2023)
  • Table 86. North America Montelukast API, by Application USD Million (2018-2023)
  • Table 87. North America Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 88. United States Montelukast API, by Type USD Million (2018-2023)
  • Table 89. United States Montelukast API, by Application USD Million (2018-2023)
  • Table 90. United States Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 91. Canada Montelukast API, by Type USD Million (2018-2023)
  • Table 92. Canada Montelukast API, by Application USD Million (2018-2023)
  • Table 93. Canada Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 94. Mexico Montelukast API, by Type USD Million (2018-2023)
  • Table 95. Mexico Montelukast API, by Application USD Million (2018-2023)
  • Table 96. Mexico Montelukast API, by Dosage Form USD Million (2018-2023)
  • Table 97. Montelukast API: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Montelukast API: by Type(USD Million)
  • Table 109. Montelukast API Montelukast Sodium Amorphous , by Region USD Million (2025-2030)
  • Table 110. Montelukast API Montelukast Sodium Crystalline , by Region USD Million (2025-2030)
  • Table 111. Montelukast API: by Application(USD Million)
  • Table 112. Montelukast API Asthma, , by Region USD Million (2025-2030)
  • Table 113. Montelukast API Allergic Rhinitis , by Region USD Million (2025-2030)
  • Table 114. Montelukast API Bronchospasm , by Region USD Million (2025-2030)
  • Table 115. Montelukast API Urticaria , by Region USD Million (2025-2030)
  • Table 116. Montelukast API Others , by Region USD Million (2025-2030)
  • Table 117. Montelukast API: by Dosage Form(USD Million)
  • Table 118. Montelukast API Tablets , by Region USD Million (2025-2030)
  • Table 119. Montelukast API Chewable Tablets , by Region USD Million (2025-2030)
  • Table 120. Montelukast API Oral Solutions , by Region USD Million (2025-2030)
  • Table 121. South America Montelukast API, by Country USD Million (2025-2030)
  • Table 122. South America Montelukast API, by Type USD Million (2025-2030)
  • Table 123. South America Montelukast API, by Application USD Million (2025-2030)
  • Table 124. South America Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 125. Brazil Montelukast API, by Type USD Million (2025-2030)
  • Table 126. Brazil Montelukast API, by Application USD Million (2025-2030)
  • Table 127. Brazil Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 128. Argentina Montelukast API, by Type USD Million (2025-2030)
  • Table 129. Argentina Montelukast API, by Application USD Million (2025-2030)
  • Table 130. Argentina Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 131. Rest of South America Montelukast API, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Montelukast API, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 134. Asia Pacific Montelukast API, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Montelukast API, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Montelukast API, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 138. China Montelukast API, by Type USD Million (2025-2030)
  • Table 139. China Montelukast API, by Application USD Million (2025-2030)
  • Table 140. China Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 141. Japan Montelukast API, by Type USD Million (2025-2030)
  • Table 142. Japan Montelukast API, by Application USD Million (2025-2030)
  • Table 143. Japan Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 144. India Montelukast API, by Type USD Million (2025-2030)
  • Table 145. India Montelukast API, by Application USD Million (2025-2030)
  • Table 146. India Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 147. South Korea Montelukast API, by Type USD Million (2025-2030)
  • Table 148. South Korea Montelukast API, by Application USD Million (2025-2030)
  • Table 149. South Korea Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 150. Taiwan Montelukast API, by Type USD Million (2025-2030)
  • Table 151. Taiwan Montelukast API, by Application USD Million (2025-2030)
  • Table 152. Taiwan Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 153. Australia Montelukast API, by Type USD Million (2025-2030)
  • Table 154. Australia Montelukast API, by Application USD Million (2025-2030)
  • Table 155. Australia Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Montelukast API, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Montelukast API, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 159. Europe Montelukast API, by Country USD Million (2025-2030)
  • Table 160. Europe Montelukast API, by Type USD Million (2025-2030)
  • Table 161. Europe Montelukast API, by Application USD Million (2025-2030)
  • Table 162. Europe Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 163. Germany Montelukast API, by Type USD Million (2025-2030)
  • Table 164. Germany Montelukast API, by Application USD Million (2025-2030)
  • Table 165. Germany Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 166. France Montelukast API, by Type USD Million (2025-2030)
  • Table 167. France Montelukast API, by Application USD Million (2025-2030)
  • Table 168. France Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 169. Italy Montelukast API, by Type USD Million (2025-2030)
  • Table 170. Italy Montelukast API, by Application USD Million (2025-2030)
  • Table 171. Italy Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 172. United Kingdom Montelukast API, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Montelukast API, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 175. Netherlands Montelukast API, by Type USD Million (2025-2030)
  • Table 176. Netherlands Montelukast API, by Application USD Million (2025-2030)
  • Table 177. Netherlands Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 178. Rest of Europe Montelukast API, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Montelukast API, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 181. MEA Montelukast API, by Country USD Million (2025-2030)
  • Table 182. MEA Montelukast API, by Type USD Million (2025-2030)
  • Table 183. MEA Montelukast API, by Application USD Million (2025-2030)
  • Table 184. MEA Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 185. Middle East Montelukast API, by Type USD Million (2025-2030)
  • Table 186. Middle East Montelukast API, by Application USD Million (2025-2030)
  • Table 187. Middle East Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 188. Africa Montelukast API, by Type USD Million (2025-2030)
  • Table 189. Africa Montelukast API, by Application USD Million (2025-2030)
  • Table 190. Africa Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 191. North America Montelukast API, by Country USD Million (2025-2030)
  • Table 192. North America Montelukast API, by Type USD Million (2025-2030)
  • Table 193. North America Montelukast API, by Application USD Million (2025-2030)
  • Table 194. North America Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 195. United States Montelukast API, by Type USD Million (2025-2030)
  • Table 196. United States Montelukast API, by Application USD Million (2025-2030)
  • Table 197. United States Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 198. Canada Montelukast API, by Type USD Million (2025-2030)
  • Table 199. Canada Montelukast API, by Application USD Million (2025-2030)
  • Table 200. Canada Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 201. Mexico Montelukast API, by Type USD Million (2025-2030)
  • Table 202. Mexico Montelukast API, by Application USD Million (2025-2030)
  • Table 203. Mexico Montelukast API, by Dosage Form USD Million (2025-2030)
  • Table 204. Montelukast API: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Montelukast API: by Type USD Million (2018-2023)
  • Figure 5. Global Montelukast API: by Application USD Million (2018-2023)
  • Figure 6. Global Montelukast API: by Dosage Form USD Million (2018-2023)
  • Figure 7. South America Montelukast API Share (%), by Country
  • Figure 8. Asia Pacific Montelukast API Share (%), by Country
  • Figure 9. Europe Montelukast API Share (%), by Country
  • Figure 10. MEA Montelukast API Share (%), by Country
  • Figure 11. North America Montelukast API Share (%), by Country
  • Figure 12. Global Montelukast API: by Type USD/Units (2018-2023)
  • Figure 13. Global Montelukast API share by Players 2023 (%)
  • Figure 14. Global Montelukast API share by Players (Top 3) 2023(%)
  • Figure 15. Global Montelukast API share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck Sharp & Dohme Corp (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck Sharp & Dohme Corp (United States) Revenue: by Geography 2023
  • Figure 19. Dr. Reddy’s Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 20. Dr. Reddy’s Laboratories Ltd (India) Revenue: by Geography 2023
  • Figure 21. Morepen Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 22. Morepen Laboratories Ltd (India) Revenue: by Geography 2023
  • Figure 23. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 25. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 27. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 30. Glenmark (India) Revenue: by Geography 2023
  • Figure 31. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Sandoz International GmbH (Germany) Revenue: by Geography 2023
  • Figure 33. Vintage Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Vintage Pharmaceuticals Inc (United States) Revenue: by Geography 2023
  • Figure 35. Hetero (India) Revenue, Net Income and Gross profit
  • Figure 36. Hetero (India) Revenue: by Geography 2023
  • Figure 37. Global Montelukast API: by Type USD Million (2025-2030)
  • Figure 38. Global Montelukast API: by Application USD Million (2025-2030)
  • Figure 39. Global Montelukast API: by Dosage Form USD Million (2025-2030)
  • Figure 40. South America Montelukast API Share (%), by Country
  • Figure 41. Asia Pacific Montelukast API Share (%), by Country
  • Figure 42. Europe Montelukast API Share (%), by Country
  • Figure 43. MEA Montelukast API Share (%), by Country
  • Figure 44. North America Montelukast API Share (%), by Country
  • Figure 45. Global Montelukast API: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck Sharp & Dohme Corp (United States)
  • Dr. Reddy’s Laboratories Ltd (India)
  • Morepen Laboratories Ltd (India)
  • Mylan N.V. (United States)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Glenmark (India)
  • Sandoz International GmbH (Germany)
  • Vintage Pharmaceuticals Inc (United States)
  • Hetero (India)
Additional players considered in the study are as follows:
Aurobindo Pharma (India) , Unimark Remedies (India) , Jubilant Cadista (United States) , Aamorb Pharmaceuticals (India)
Select User Access Type

Key Highlights of Report


Apr 2024 211 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Montelukast API Market Quantitative research analysis
Global Montelukast API Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Sharp & Dohme Corp (United States), Dr. Reddy’s Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd (Israel), Hikma Pharmaceuticals PLC (United Kingdom), Glenmark (India), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (United States) and Hetero (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Implementation of Rules and Regulations in Montekulast API market." is seen as one of major influencing trends for Montelukast API Market during projected period 2023-2030.
The Montelukast API market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Montelukast API Market Report?

Have a Query? Click Here

Other Related Reports

Drug & Pharmaceuticals & Cosmetics Retail Comprehensive Study by Type (Cosmetic, Pharmaceutical), Application (Child, Women, Men), Channel (Direct Sales, Distribution Channel) Players and Region - Gl...
$ 3400
Immune Boosting Supplement Comprehensive Study by Type (Vitamin C Supplements, Vitamin D Supplements, Vitamin B Supplements, Selenium Supplements, Zinc Supplements, Herbal Supplements, Probiotic Supp...
$ 3800
3D Printing Drug Comprehensive Study by Type (Spritam, Others), Application (Neurology, Hearing and Audibility Aid, Dental, Medical Implants, Others), End User (Hospitals, Clinics and, Research Labor...
$ 3800